366 related articles for article (PubMed ID: 37097594)
1. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus.
Verwey C; Madhi SA
BioDrugs; 2023 May; 37(3):295-309. PubMed ID: 37097594
[TBL] [Abstract][Full Text] [Related]
2. Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date.
Verwey C; Dangor Z; Madhi SA
Paediatr Drugs; 2024 Mar; 26(2):101-112. PubMed ID: 38032456
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
5. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
[TBL] [Abstract][Full Text] [Related]
6. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
[TBL] [Abstract][Full Text] [Related]
7. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
Scotta MC; Stein RT
J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
[TBL] [Abstract][Full Text] [Related]
11. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus disease: update on treatment and prevention.
Krilov LR
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
[TBL] [Abstract][Full Text] [Related]
13. RSV disease in infants and young children: Can we see a brighter future?
Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
[TBL] [Abstract][Full Text] [Related]
15. Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?
Karron RA; Zar HJ
Lancet Respir Med; 2018 Jan; 6(1):65-74. PubMed ID: 28865676
[TBL] [Abstract][Full Text] [Related]
16. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
[TBL] [Abstract][Full Text] [Related]
18. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
[TBL] [Abstract][Full Text] [Related]
20. Nirsevimab: A Review.
Balbi H
Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
